Professor Tang Yi: Memory, Dementia, and Early Alzheimer’s Specialist
Professor Tang Yi is a senior neurologist, professor, doctoral supervisor, executive vice president of Xuanwu Hospital, and executive deputy director of the National Center for Neurological Disorders. His clinical and academic work focuses on Alzheimer’s disease, mild cognitive impairment, other dementias, early diagnosis, biomarkers, digital cognitive therapy, non-invasive brain stimulation, and clinical trials.
Clinical and Academic Focus
- mild cognitive impairment;
- Alzheimer’s disease;
- frontotemporal and Lewy body dementia;
- vascular and mixed cognitive impairment;
- early diagnosis and biomarker interpretation;
- computerized cognitive training;
- non-invasive brain stimulation;
- disease-modifying therapy assessment; and
- second opinions for uncertain or rapidly changing cognition.
Memory Change and Mild Cognitive Impairment
Mild cognitive impairment describes measurable decline greater than expected for age while everyday independence is largely preserved. Some people remain stable or improve, while others progress to dementia.
Evaluation should consider memory, language, attention, executive function, visuospatial ability, mood, sleep, medication, hearing, vision, and daily function. Memory complaints alone do not establish Alzheimer’s disease.
Diagnosing Alzheimer’s Disease
Diagnosis combines history from the patient and family, neurological examination, cognitive testing, structural brain imaging, and evaluation for reversible contributors.
Biomarkers may include cerebrospinal-fluid testing, amyloid PET, tau PET where available, or validated blood tests. Results should be interpreted in context because abnormal amyloid does not explain every symptom.
Other Causes of Cognitive Decline
Cognitive symptoms can result from vascular disease, Lewy body disease, frontotemporal degeneration, Parkinson’s disease, normal-pressure hydrocephalus, depression, sleep apnea, seizures, autoimmune disease, infection, thyroid disease, vitamin deficiency, medication, or substance use.
Rapidly progressive symptoms require urgent evaluation for potentially treatable causes.
Symptomatic Treatment
Medicines such as cholinesterase inhibitors or memantine may improve or stabilize symptoms for some patients. Treatment of sleep, mood, hearing, vascular risk, pain, and medication burden can also improve function.
Care plans should include exercise, social and cognitive activity, nutrition, home safety, driving assessment, caregiver support, and future planning.
Disease-Modifying Therapy
Anti-amyloid therapies may slow decline in selected patients with early symptomatic Alzheimer’s disease and confirmed amyloid pathology. They do not restore lost memory or cure the condition.
Eligibility requires careful assessment of disease stage, MRI findings, bleeding risk, anticoagulant use, APOE status where relevant, and ability to complete repeated infusions and MRI monitoring. Brain swelling or microbleeding can occur.
Computerized Cognitive Training
Professor Tang’s team has studied dose-response relationships between computerized cognitive training and cognitive improvement. Digital programs can support structured practice, but benefits depend on adherence, task design, baseline ability, and transfer to everyday function.
Digital therapy should complement rather than replace medical evaluation, exercise, sleep care, and social engagement.
Transcranial Alternating Current Stimulation
Transcranial alternating current stimulation, or tACS, applies weak electrical currents through scalp electrodes to influence brain rhythms. Professor Tang has participated in randomized research evaluating tACS in mild Alzheimer’s disease.
This remains an evolving area. Protocol, equipment, supervision, contraindications, and realistic expectations are essential.
Clinical Trials
Professor Tang has led and participated in national and international Alzheimer’s clinical trials. Eligibility depends on diagnosis, biomarker status, disease stage, health, medication, timing, and current recruitment.
Who May Consider a Consultation?
- patients with persistent memory or thinking change;
- patients with mild cognitive impairment;
- patients with an uncertain dementia diagnosis;
- patients with rapid or unusual cognitive decline;
- patients considering biomarker testing;
- patients assessing disease-modifying treatment;
- patients interested in cognitive training, brain stimulation, or a clinical trial; or
- families seeking a second opinion on prognosis and care planning.
Medical Records to Prepare
- a concise cognitive, behavioral, and functional timeline from patient and family;
- brain MRI, CT, PET, and SPECT in original DICOM format;
- formal cognitive and neuropsychological test results;
- blood and cerebrospinal-fluid biomarker reports;
- amyloid and tau testing when available;
- sleep, mood, hearing, vision, seizure, and vascular assessments;
- genetic reports and family history when relevant;
- a complete medication and supplement list;
- examples of changes in finances, cooking, driving, medication, or navigation; and
- a clear list of diagnosis, safety, and treatment goals.
Planning an International Consultation
Sudden confusion, new weakness, seizure, fever, head injury, or rapidly progressive cognitive change requires urgent local assessment.
Stable patients should confirm whether imaging, cognitive testing, and biomarker records can be reviewed. Remote medical-record review requires physician authorization. Final diagnosis, treatment, stimulation, or trial eligibility usually requires in-person neurological and cognitive assessment.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients and families with organizing and translating cognitive-disorder records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.
Access to Professor Tang, remote review, biomarker testing, disease-modifying therapy, brain stimulation, or a clinical trial is subject to doctor and hospital approval. CMCS does not guarantee appointments, diagnosis, treatment eligibility, trial enrollment, or clinical outcomes.
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor titles, clinical roles, medicines, tests, devices, trial availability, and appointment arrangements may change. This profile is based on the supplied verified research document and is for general information only. It does not replace assessment by a qualified cognitive-neurology team.
0 comentarios